Collumbotai Bio-B (06990): SKB445 new drug clinical trial application approved by the State Drug Administration

Zhitongcaijing · 01/20 12:17

Zhitong Finance App News, Colunbotai Bio-B (06990) issued an announcement. The company's board of directors is pleased to announce that on January 20, 2025, the company received a clinical trial notice from the Drug Evaluation Center of the State Drug Administration agreeing to the clinical trial application for the innovative drug SKB445 developed by the company.

SKB445 is a novel ADC drug with independent intellectual property rights developed by the company using OptiDC TM platform technology for target biological characteristics. It has shown good efficacy and safety window in preclinical studies, and is intended for the treatment of advanced solid tumors.